Rapid comparative evaluation of SARS-CoV-2 rapid point-of-care antigen tests

- 3 Anna Denzler^{1,†}, Max L. Jacobs^{1,†}, Victoria Witte¹, Paul Schnitzler², Claudia M.
- 4 Denkinger^{3,*}, Michael Knop^{1,4,5,*}

Affiliations:

1

2

5

6

1718

212223

24

35

- 7 Center for Molecular Biology of Heidelberg University (ZMBH), Heidelberg,
- 8 Germany.
- 9 ² Department of Infectious Diseases, Virology, Heidelberg University Hospital,
- 10 Heidelberg, Germany.
- Department of Infectious Diseases, Division of Tropical Medicine, Heidelberg
- 12 University Hospital, Heidelberg, Germany.
- 13 ⁴ German Cancer Research Center (DKFZ), Heidelberg, Germany.
- ⁵ DKFZ-ZMBH Alliance, Heidelberg, Germany.
- 15 * Corresponding authors.
- 16 [†] These authors contributed equally to this work.
- 19 **Keywords:** Comparison of Antigen-detecting rapid diagnostic test; COVID-19;
- 20 SARS-CoV-2; Testing sensitivity, non-functional AgPOC tests.

Corresponding authors:

- 25 Michael Knop
- 26 Center for Molecular and Cellular Biology Heidelberg, Heidelberg University,
- 27 Heidelberg, Germany
- 28 m.knop@zmbh.uni-heidelberg.de
- 29 +49 6221 54 4213
- 30 Claudia M. Denkinger
- 31 Division of Tropical Medicine, Center for Infectious Diseases, Heidelberg University
- 32 Hospital, Heidelberg, Germany
- 33 Chartections, proprint imports induction to the host of the host of the host of the control of the host of the
- 34 +49 6221 56 36637

perpetuity.

It is made available under a CC-BY-ND 4.0 International license .

Abstract

36

- 37 Background: Currently, more than 500 different AgPOCTs for SARS-CoV-2
- diagnostics are on sale, for many of which no data about sensitivity other than self-
- 39 acclaimed values by the manufacturers are available. In many cases these do not
- 40 reflect real-life diagnostic sensitivities. Therefore, manufacturer-independent quality
- 41 checks of available AgPOCTs are needed, given the potential implications of false-
- 42 negative results.
- 43 **Objective:** The objective of this study was to develop a scalable approach for direct
- 44 comparison of the analytical sensitivities of commercially available SARS-CoV-2
- antigen point-of-care tests (AgPOCTs) in order to rapidly identify poor performing
- 46 products.
- 47 Methods: We present a methodology for quick assessment of the sensitivity of
- 48 SARS-CoV-2 lateral flow test stripes suitable for quality evaluation of many different
- 49 products. We established reference samples with high, medium and low SARS-CoV-
- 2 viral loads along with a SARS-CoV-2 negative control sample. Test samples were
- 51 used to semi-quantitatively assess the analytical sensitivities of 32 different
- 52 commercial AgPOCTs in a head-to-head comparison.
- 53 Results: Among 32 SARS-CoV-2 AgPOCTs tested, we observe sensitivity
- differences across a broad range of viral loads (~7.0*10⁸ to ~1.7*10⁵ SARS-CoV-2
- 55 genome copies per ml). 23 AgPOCTs detected the Ct25 test sample (~1.4*106
- copies/ ml), while only five tests detected the Ct28 test sample (~1.7*10⁵ copies/
- 57 ml). In the low range of analytical sensitivity we found three saliva spit tests only
- delivering positive results for the Ct21 sample (~2.2*10⁷ copies/ ml). Comparison
- 59 with published data support our AgPOCT ranking. Importantly, we identified an
- 60 AgPOCT offered in many local drugstores and supermarkets, which did not reliably
- recognize the sample with highest viral load (Ct16 test sample with ~7.0*10⁸ copies/
- 62 ml) leading to serious doubts in its usefulness in SARS-CoV-2 diagnostics.
- 63 **Conclusion:** The rapid sensitivity assessment procedure presented here provides
- 64 useful estimations on the analytical sensitivities of 32 AgPOCTs and identified a
- widely-spread AgPOCT with concerningly low sensitivity.
- 68 **Funding:** The study was supported by the Ministry of Science, Research and Arts of
- 69 the State of Baden-Wuerttemberg, Germany as well as internal funds from the
- Heidelberg University Hospital. The corresponding authors had access to all data at
- 71 all time.

66

67

72

Introduction

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

In the SARS-CoV-2 pandemic, lateral-flow antigen tests were developed as a rapid alternative to SARS-CoV-2 reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) based diagnostics. Because of their ease of use, lateral-flow antigen tests are applicable for point-of-care and self testing and can therefore be incorporated in the daily life to support viral containment (WHO, Interim guidance, 2020). These tests, in the following referred to as antigen point-of-care tests (AgPOCTs), are meanwhile widely used for SARS-CoV-2 diagnostic and screening purposes. Currently, several hundred different SARS-CoV-2 AgPOCTs brands are commercially available to meet the demand (545 products for professional use are listed by the Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM)); as of July 27, 2021). However, sensitivity and specificity of the tests are not systematically assessed. If a test is used by a professional operator, it falls under the 'low-risk' category of the European Union directive on In Vitro Diagnostics (IVD), which currently governs marketing authorization for IVDs in Europe. Under this directive, manufacturers can still self-certify COVID-19 tests and waive independent verification of the tests before they are marketed. The validation of the tests, which are offered on the Internet and in pharmacies, is therefore not assured in the view of the Paul Ehrlich Institute (PEI), Federal Institute for **Vaccines** and Biomedical Products, Germany (https://www.pei.de/DE/newsroom/hp-meldungen/2020/200323-covid-19-nattests.html;jsessionid=F786872EBB85959AE8DA2B8FCB3ABE00.intranet222?nn=16 9730). There is also evidence of counterfeiting here. A new legislation governing independent validation by specialized and certified reference laboratories is planned, but will only become effective in March 2022 at the earliest.

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

If a test is distributed for layperson use, it falls under a 'higher-risk' category and requires independent validation. This validation of sensitivity is currently performed by the PEI together with reference laboratories and a list with AgPOCTs passing their criteria is provided (PEI, 2021). AgPOCTs failing the comparative evaluation by PEI will be removed from the list provided by BfArM. This list, however, comprises only products, which were also registered for listing by manufacturers or distributors (https://www.bfarm.de/DE/Medizinprodukte/Aufgaben/Spezialthemen/Antigentests/_n ode.html), rendering the absence of an AgPOCT from this list difficult to interpret. Many in-depth AgPOCT characterization studies show that AgPOCT sensitivities can vary substantially. One study reporting on the validation of 122 AgPOCs has recently been published (Scheiblauer et al., 2021). They found that 26 AgPOCTs do not fulfill the required minimum sensitivity, clearly illustrating that quite a number of circulating AgPOCT are insufficiently sensitive. In addition to this, significant brand-to-brand and lot-to-lot variations were observed (Dinnes et al, 2021). These circumstances urge the need for an easy-to-use method to guickly assess AgPOCTs at market entry and periodically thereafter for post-implementation quality control. In this study, we seeked to establish a procedure to rapidly evaluate a large number of products for their sensitivity, using only a few samples and tests per product. For this we developed a strategy involving pooled samples and four different dilution steps from high to low viral loads, and generated several hundred aliquots thereof. Using this approach we then investigated 32 AqPOCTs, mainly tests currently in use in the local area (Heidelberg, Germany). We compared the results with data from the literature, which enabled us to draw conclusions on the validity of our approach and the performance of the products investigated.

Methods

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

Study design

We tested the analytical sensitivity of a large number of commercially available AgPOCTs by applying pooled samples from nasopharyngeal swabs with defined SARS-CoV2 viral loads including Ct16, Ct21, Ct25 and Ct28 (~7.0*108 to ~1.7*105 genome copies per ml) as well as a pooled sample obtained from SARS-CoV-2 negative tested persons. Pools were generated using pseudo-anonymized remnant swab sample material that had been collected for clinical diagnosis of SARS-CoV-2 infection by RT-qPCR carried out by the Center for Infectious Diseases, Virology, Heidelberg University Hospital, Germany, Pharyngeal swab specimens were collected through the nose (nasopharyngeal) and contained in viral transport medium (VTM). Per test, 50 µl of the samples were mixed with the provided lysis buffer of each AgPOCT and the tests were performed according to the manufacturer's instructions. After the recommended incubation time, images of the test chambers were acquired using a Panasonic Lumix DMC-G70 camera equipped with a Panasonic H-FS12060 objective. AgPOCTs were tested at least in duplicates with the corresponding test samples. Test results were quantified by measuring the background corrected signal intensities of the test (T) band versus control (C) band in ImageJ (v1.53c) using the "Gels" analysis function usually used for quantification of Western Blot bands. For qualitative evaluation of the visibility of the test bands (positive versus negative score), RGB pictures of AgPOCT results from randomly chosen replicates were evaluated independently by three individuals in a blinded manner. Furthermore, all additional replicates of all AgPOCTs and test samples were scored independently by another person.

Preparation of test samples from nasopharyngeal swabs

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

Anonymized, remnant nasopharyngeal swab samples positively and negatively tested for SARS-CoV-2 were obtained between May and July 2021 from the the Center for Infectious Diseases, Virology, Heidelberg University Hospital, Germany. Samples were stored in VTM. The Ct16, Ct21 and negative test samples were prepared by pooling of 12-15 nasopharyngeal swab samples. Cell debris and other solids were removed by centrifugation at 400g for 10min and subsequent transfer of the supernatant into a new tube. Viral RNA was isolated from pools by manual lysis and automated RNA extraction using the QIAamp Viral RNA Mini kit (Qiagen) on a QIAcube Connect device (Qiagen). The cycle threshold (Ct) values of sample pools were determined by RT-qPCR analysis using the LightMix® Modular Sarbecovirus SARS-CoV-2 (TIB Molbiol) with the LightCycler® Multiplex RNA Virus Master (Roche) and LightCycler480 II (Roche). Subsequently, pools were supplemented with 2 % TritonX-100 and c0mplete Ultra protease inhibitor (Roche) and if needed adjusted with dilution buffer [2 mg/ ml BSA, 0.9 % NaCl, protease inhibitor]. Ct25 and Ct28 test samples were prepared by dilution of the Ct21 test sample in the dilution buffer. Samples were aliquoted (120 µl), immediately frozen on dry ice and stored at -80°C. For AgPOCT testing, samples were freshly thawed on ice before use. Test samples were validated using the SARS-CoV-2 Antigen Test by LumiraDx.

AgPOCTs evaluated in this study

We included a total of 32 AgPOCTs available at local supermarkets, pharmacies and drugstores as well as on several online trade platforms (Table 1). Specific AgPOCTs will be referred to as the respective manufacturer's name (in bold in Table 1). The inspected AgPOCTs include both, tests for professional *in vitro* diagnostics use (#1-14) as well as tests temporarily licensed for self-testing in Germany (#15-32) by the Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM); Supplemental Figure S3). The majority of AgPOCTs available were nasal swab tests with the exception of BTNX, Ritter, Joinstar, Realy (#11-14) among the tests for professional use and Sanicom, Hygisun, fameditec (#30-32) among the self tests, which are all saliva spit tests, as well as Watmind (#29), which is a saliva swab test.

Table 1: AgPOCTs investigated in this study. For each AgPOCT supplier, name, reference and LOT number are indicated. If tests obtained a temporary license for self-testing in Germany the corresponding BfArM GZ number is given as well. In addition, sample type and professional (pro) versus layman (lay) use is indicated. In the last column the type of distributor where AgPOCTs were purchased is noted.

#	Supplier	AgPOCT name	Specifications	Sample type	Use	Distributor	
1	Abbott Rapid	Panbio COVID-19 Ag Rapid	REF: 41FK11	Nasal swab	pro	Online trade	
	Diagnostics Jena GmbH	test device (nasal)	LOT: 41ADG244A				
2	Healgen Scientific	Coronavirus Ag Rapid Test	REF: GCCOV-502a	Nasopharyngeal	pro	Online trade	
	Limited Liability Company	Cassette (Swab)	LOT: 2012650	swab			
3	RapiGEN, INC.	Biocredit COVID-19 Ag – One	REF: G61RHA20	Nasopharyngeal	pro	Online trade	
		step Rapid Test	LOT: H073097SD	swab			
4	Beijing Beier	COVID-19 Antigen Rapid Test	REF: not specified	Nasopharyngeal	pro	Online trade	
	Bioengeneering Co., Ltd	Kit	LOT: 20210201	swab			
5	möLab GmbH	mö-screen Testkit Corona	REF: 0230005B1	Nasal/	pro	Online trade	
		Antigen	LOS: 2104072	Nasopharyngeal swab			
6	Biomerica, Inc.	COVID-19 Antigen Rapid Test	REF: 1509A-25I	Nasopharyngeal	pro	Online trade	
			LOT: COV6686	swab			
7	Joysbio (Tianjin)	JOYSBIO SARS-CoV-2	REF: G10313	Nasopharyngeal	pro	Online trade	
	Biotechnology Co., Ltd	Antigen Rapid Test Kit (Colloidal Gold)	LOT: 2021011607	swab			

8	Safecare Biotech	COVID-19 Antigen Rapid Test	REF: COV Ag-6012	Nasopharyngeal	pro	Online trade	
	(Hangzhou) Co., Ltd	Kit (Swab)	LOT: COV21040606	swab			
9	Hangzhou Testsea	Testsealabs COVID-19	REF: 2020013 vB/10	Nasal swab	pro	Online trade	
	Biotechnology Co., Ltd	Antigen Test Cassette	LOT: TL1C05				
10	ACON Biotech (Hangzhou) Co., Ltd	Flowflex SARS-Cov-2-Antigen- Schnelltest (Selbsttest)	REF: L031-11855 LOT: COV1030052	Nasal swab	pro	Online trade	
11	BTNX Inc.	Rapid Response COVID-19	REF: COV-2C25B	Saliva (spit)	pro	Online trade	
		Antigen Rapid Test Cassette	LOT: COVG21030089				
12	Joysbio (Tianjin)	Easy Check Spit test SARS-	REF: COV-AG-20/ G10313	Saliva (spit)	pro	Online trade	
	Biotechnology Co., Ltd/ Ritter	CoV-2 Antigen Rapid Test Kit (Colloidal Gold)	LOT: 20210202				
13	Joinstar Biomedical	COVID-19 Antigen Rapid Test	REF: RPBH12360	Saliva/ sputum	pro	Online trade	
	Technology Co., Ltd.	(Latex)	LOT: COV2103002L	(spit), stool			
14	Hangzhou Realy Tech	Novel Coronavirus (SARS-	REF: K590516D	Saliva (spit)	pro	Online trade	
	Co., Ltd	CoV-2) Antigen Rapid Test Device (Saliva)	LOT: 202101022				
15	nal von minden	NADAL COVID-19 Ag Test	REF: 243103N-20H	Nasal swab	lay	Online trade	
	GmbH		LOT: 175363				
			BfArM GZ: 5640-S-045/21				
	•	·					

16	SD Biosensor	SARS-CoV-2 Rapid Antigen Test	REF: 9901-NCOV-01G LOT: QCO390092I BfArM GZ: 5640-S-025/21	Nasal swab	lay	Online trade
17	Beijing Hotgen Biotech Co., Ltd	Coronavirus (2019-nCoV)- Antigentest	REF: 4260220532859 LOT: W2021032500/ W2021032602/ 1500 BfArM GZ: 5640-S-057/21	Nasal swab	lay	Supermarket Pharmacy
18	Guangzhou Wondfo Biotech Co., Ltd.	2019-nCoV Antigen Test (Lateral Flow Method)	REF: W634P0021 LOT: W634104116 BfArM GZ: 5640-S-179/21	Nasal swab	lay	Supermarket
19	Teda Laukoetter Technology GmbH	COVID-19 Antigen Schnelltest (kolloidales Gold) ANBIO Corona Antigen Nasentupfer	REF: A6061214 LOT: 2021046133/ 461310/036138 BfArM GZ: 5640-S-079/21	Nasal swab	lay	Drug store
20	Beijing Lepu Medical Technology Co., Ltd	NASOCHECKcomofort SARS- CoV-2 Antigen-Schnelltest	REF: CG2701N LOT: 21CG2720X/ 18X BfArM GZ: 5640-S-104/21	Nasal swab	lay	Drug store
21	Hangzhou Clongene Biotech Co., Ltd	COVID-19 Antigen Rapid Test	REF 6950921302636 LOT: 2021030161 BfArM GZ: 5640-S-168/21	Nasal swab	lay	Online trade
22	Hangzhou Laihe Biotech Co., Ltd	LYHER Novel Coronavirus (COVID-19) Antigen Test Kit (Colloidal Gold) NASAL	REF: 303036 LOT: 2103049/47/ 89-01 BfArM GZ: 5640-S-009/21	Nasal swab	lay	Pharmacy

23	MP Biomedicals Germany GmbH	Rapid SARS-Cov-2 Antigen Test Card	REF: 07AG6001BS LOT: 21033003	Nasal swab	lay	Supermarket	
			BrArM GZ: 5640-S-076/21				
24	Xiamen Boson Biotech Co., Ltd	Rapid SARS-CoV-2 Antigen Test Card	REF: 1N40C5-4 LOT: 21040609	Nasal swab	lay	Supermarket	
			BfArM GZ: 5640-S-007/21				
25	NanoRepro AG	VIROMED for the detection of SARS-Cov-2 from anterior	REF: B60500 LOT: 20210401B	Nasal swab	lay	Drug store	
		nasal swab	BrArM GZ: 5640-S-096/21				
26	Anhui Deepblue Medical Technology	COVID-19 (SARS-CoV-2) Antigentestkit (kolloidales	REF: SL030101N-5 LOT: ST210405	Nasal swab	lay	Online trade	
	Co., Ltd	Gold)	BfArM GZ: 5640-S-086/21				
27	OFM GmbH	Deni COVID-19 Antigen Test –	REF: OFM-LSYBT-NS-1	Nasal swab	lay	Drug store	
		Selbsttest für ZuHause	LOT: P202103003			J	
			BfArM GZ: 5640-S-140/21				
28	Medice Arzneimittel	Medicovid-AG SARS-CoV-2	REF: 1N40C5-4	Nasal swab	lay	Online trade	
	Pütter GmbH & Co. KG	Antigen Selbsttest 5 NASE	LOT: 21041002				
	NG		BfArM GZ: 5640-S-128/21				
29	Shenzhen Watmind Medical Co., Ltd	SARS-CoV-2 Antigen Schnelltest zur	REF: LFA0401-5N LOT: 21040904/ 21040704	Saliva (swab) lay		Supermarket	
	,	Eigenanwendung (kolloidales Gold)	BfArM GZ: 5640-032/21	ArM GZ: 5640-032/21			

30	MR Sanicom GmbH	COVID-19 Antigen Schnelltest zur Eigenanwendung (Speichel-/ Spucktest)	Barcode no: 4260729310002 LOT: CAG2104021G BfArM GZ: 5640-S-147/21	Saliva (spit)	lay	Drug store
31	Hygisun Anbio (Xiamen) Biotechnology Co., Ltd.	COVID-19 Antigen Schnelltest (kolloidales Gold)	REF: A6061213 LOT: 2021046132/ 2021036136/ 2021036137 BfArM GZ: 5640-S-058/21	Saliva (spit)	lay	Drug store
32	fameditec	CORA Check-19 Comfort	REF: K590516D/ LOT: 2021022019 BfArM GZ: 5640-S-154/21	Saliva (collected with sponge)	lay	Online trade

Results

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

Generation of test samples for standardized AgPOCT evaluation

In the present study, we sought to establish a standardized procedure to rapidly assess the sensitivities of a large number of SARS-COV-2 AgPOCTs. To this end, we generated a collection of test samples from pooled nasopharyngeal swabs from SARS-CoV-2 positive tested and negative tested individuals. Ct values of the SARS-CoV-2 positive pools were determined by RT-qPCR and test samples were prepared accordingly. The test sample collection comprised four SARS-CoV-2 positive pools with defined viral loads (Ct16, Ct21, Ct25, Ct28) and one SARS-CoV-2 negative pool. Per test sample, >200 aliquots with 120 µł sample volume each were prepared, allowing a quick and standardized evaluation of the analytical sensitivities of a large number of different AgPOCTs. We estimated that our test sample collection covers a range from ~7.0*108 (Ct=16) to ~1.7*10⁵ (Ct=28) SARS-CoV-2 genome copies per ml (Supplemental Table S4). We qualitatively validated our test sample collection using the LumiraDx SARS-CoV-2 Ag Test device, which was shown to have a high analytical sensitivity (Krüger et al., 2021). We used 50 µl of test sample for the LumiraDx analysis as well as for all AgPOCTs evaluated in this study, as described before (Corman et al., 2021; Puyskens et al., 2021). All four SARS-CoV-2 positive test samples tested positive for SARS-CoV-2, while the negative test sample was recognized as negative in the LumiraDx analysis.

Quantitative and qualitative assessment of AgPOCT analytical sensitivity

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

We tested a total of 32 AgPOCTs (Table 1). 12 AgPOCTd were purchased from local resellers (pharmacies, drugstores, supermarkets). Another 20 tests were purchased online. We performed the tests over 10 days, with the help of four students, during the course of four weeks. Freshly thawed aliquots of the Ct21, Ct25, and Ct28 test samples as well as the negative sample were used. We conducted two to four replicates per product, and acquired images of each of the tests at the time points specified by the manufacturers. The Ct16 test sample was only used for AgPOCTs that had low performance with the Ct21 test sample. For quantitative evaluation, signal intensities of the test and the control bands were measured and the ratio of these values (T/C ratio) was determined (Figure 1A). In addition, we scored a binary (positive or negative) test result using visual inspection of the images by four different persons (Figure 1B). For 31 of 32 investigated AgPOCTs, an average T/C_{Ct25}>0 was determined for all virus-containing samples and not for the negative control sample (Figure 1A). This indicates that the digital quantification detects test band signals for 31 AgPOCTs using the Ct25 test sample, albeit sometimes with extremely weak signal intensities. Only for Jointstar, one replicate of the negative test sample resulted in a falsepositive test band indicated by a T/C_{Neg.}>0. In contrast to the more sensitive digital quantification, visual inspection did only score a positive result for 28 of 31 AqPOCTs with a T/C_{Ct25}>0. This also holds true for the visual assessment of the results of technical replicates, e.g. for Jointstar, the negative sample with a T/C_{Neg.}>0 scored negative in the visual inspection. We could not establish a specific T/C value threshold to explain the results of the visual assessment, indicating that these ratios are AgPOCT-specific. This can be explained by different dyes and dye-systems, and

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

by the fact that the visual assessment was conducted using color vision, while for T/C quantification grayscale images were used. We also observed a large coefficient of variation for some of the tests, in particular for samples with very small T/C ratios, emphasizing weak signals close to the detection limit of the digital quantification (Supplemental Figure S1). We grouped the tested AgPOCT into categories with low (Group III), medium (Group II) and high (Group I) sensitivity based on the reliability to detect a given SARS-CoV-2 positive sample. A sample was considered reliably detected by a given AgPOCT when all or the majority of replicates (at least two out of three or three out of four replicates) of a given sample were scored positive. If none or the minority of replicates of a given sample was detected by the corresponding AgPOCT, reliability requirements were not met. One exception was Lepu Medical, which did not fulfill the requirements for any of these groups. For Group III with lowest sensitivity the minimum criterion was to reliably detect the Ct21 sample and Lepu medical did not even reliably score positive with the Ct16 sample (~7.0*10⁸ copies/ ml). To investigate this product further and exclude a possible interference of the components in the dilution buffer with AgPOCT performance we used individual unprocessed nasal/ nasopharyngeal swab samples in comparison to the Ct16 test sample (pool) on this AgPOCT. Ct values of unprocessed samples ranged from Ct13,3 to Ct18,4. Comparison of the corresponding results obtained for the Ct16 test sample to results obtained for unprocessed samples confirmed that components of the dilution buffer do not impact on AgPOCT performance compared to unprocessed samples in VTM (Supplemental Figure S2). As unprocessed samples with higher viral loads (Ct~13) induced more visible test bands with Lepu medical (Supplemental Figure S2A), this product does

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

non-functional. not seem completely but rather largely insensitive. AgPOCTs in Group III only reliably detected the Ct21 sample (~2.2*10⁷ copies/ ml) and include Hygisun, Joinstar and Ritter. Of note is that all of them are saliva based spit tests (Table 1), which are provided with a considerably larger amount of lysis buffer (500-1000 µl lysis buffer; Figure 1C) than most other AgPOCTs resulting in an increased dilution of the sample compared to tests for nasal samples, which are provided on average with 320 µl lysis buffer (Figure 1C). Therefore, their low performance in this AgPOCT evaluation study needs to be interpreted with caution. The large majority of the investigated AgPOCTs (23 out of 32) delivered visible positive results with the Ct25 sample (~1.4*106 copies/ ml, Group II). Among these 23 AgPOCTs, positive scoring was fully reproducible in all replicates for 17 AgPOCTs. AgPOCTs intended for professional use (sorted ascending according to T/C_{Ct25}: Safecare, Realy, Healgen, ACON, Beier, Testsea, BTNX and Biomerica) largely cluster in the upper half of the T/C_{Ct25} ranking, while tests licensed for selftesting largely cluster in the lower half (sorted ascending according to T/C_{Ct25}: Sanicom, fameditec, OFM, Deepblue, NanoRepro, nal von minden, Teda, Laihe and Boson). Interestingly, among both tests for professional and for layman use, saliva spit tests (Realy, Sanicom, fameditec) appear largely inferior compared to nasal swab tests with the exception of BTNX, which is the sixth highest ranked AgPOCT among all investigated tests. Six AgPOCTs in Group II (sorted ascending according to T/C_{Ct25}: Joysbio, RapiGEN, Hotgen, SD Biosensor, Abbott and Wondfo) failed in one out of three to four replicates to detect the Ct25 sample, which is represented by coefficient large of variation (Supplemental Figure S1). а Using the Ct28 test sample (~1.7*10⁵ copies/ ml), 14 out of 32 AgPOCTs yielded a T/C_{Ct28}>0, however, only five reliably scored positive in the visual investigation (Group I). These include (sorted in ascending order according to T/C_{Ct25}) möLab,

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

Medice, MP, Clongene and Watmind, three of which are temporarily licensed for selftesting (Table 1, Supplemental Figure S3). All, except möLäb delivered a positive visual result in all three replicates. Taken together, the data presented here demonstrate that the different SARS-CoV-2 AgPOCTs available deviate largely in the analytical sensitivity of the lateral flow test stripes and provided buffer systems, corresponding more than two orders of magnitude of viral genome copies per ml $(7.0*10^8 \text{ to } 1.7*10^5)$. **Discussion** We developed a straight-forward strategy to evaluate the technical sensitivity of AgPOCTs for SARS-CoV-2. Using a set of four SARS-CoV-2 positive reference samples spanning the relevant dynamic range of the typical sensitivity of AgPOCTs (~1.7*10⁵ to ~2.2*10⁷ SARS-CoV-2 genome copies per ml) we were able to group 32 commercially available products into AgPOCT groups with high, average and low sensitivity (Group I-III). Most importantly, we identified one product that did not detect any of the test samples and therefore is considered not suitable for SARS-CoV-2 diagnostics. The majority of tests investigated in this study reliably detected the Ct25 test sample as SARS-CoV-2 positive (Group II). Some of these AgPOCTs have been thoroughly characterized, including Abbott, RapiGEN, Healgen, nal von minden and SD Biosensor by Corman and colleagues (Corman et al., 2021) among others (Strömer

et al., 2021; Stokes et al., 2021; Merino et al., 2021; Schildgen et al., 2021;

Seynaeve et al., 2021; Nordgren et al.; Puyskens et al., 2021; Scheiblauer et al.,

2021; Kohmer et al., 2021; Wagenhäuser et al., 2021; Berger et al., 2021;

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

Jegerlehner et al., 2021; Iglòi et al., 2021; Bekliz et al., 2021; Cubas-Atienzar et al., 2021, Haage et al., 2021 and more). Corman and colleagues determined 95% limits of detection for each AgPOCT using 138 SARS-CoV-2 positive clinical samples with viral loads ranging from 1.9*10⁴ to 1.8*10⁹ genome copies per ml. Among the AgPOCTs also tested in this study, Healgen was found to be most sensitive closely followed by Abbott, SD Biosensor and nal von minden - all with a 95% limit of detection between 2.3 - 9.3*10⁶ SARS-COV-2 genomes per swab. In contrast, for RapiGEN a 95% limit of detection more than three orders of magnitudes lower was found. This discrepancy in performance between RapiGEN and the above mentioned products is supported by other studies (Brümmer et al., 2021). In our analysis, this trend is also reflected even though we cannot resolve the limits of detection in such great detail: For Healgen and nal von minden, detection of the Ct25 sample (~1.4*10⁶ copies/ ml) was robust with all replicates being positively scored. For RapiGEN, Ct25 test sample detection was less reliable and based on the T/C_{Ct25}, this product is ranked in the lowest quarter among all AgPOCTs investigated. Among the 32 investigated AgPOCTs, we identified four reliably well performing AgPOCTs, which detected the Ct28 sample (~1.7*10⁵ copies/ ml) as SARS-CoV-2 positive in all replicates (Group I). These include in ascending order (based on T/C_{Ct25}) Medice, MP, Clongene and Watmind. The latter represents the test winner in our study and is also among the best three AgPOCTs out of 122 tested products with a sensitivity of 82 % in samples with Ct values ranging from 17 to 35 corresponding to viral loads of >108 to 103 SARS-CoV-2 genome copies per ml (Scheiblauer et al., 2021). Group III includes AgPOCTs with low performance as these only detected the Ct21 test sample as SARS-CoV-2 positive. For Joinstar, using Latex beads for

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

visualisation, evidence provided by Scheiblauer and colleagues (2021) suggests that this test is non-functional with 0% sensitivity for all sample panels supporting the low ranking of Joinstar in this study. In our analysis we detected very weak bands for the Ct21 and Ct16 test samples, however, these were considerably weaker than for all other tests suggesting the possibility that latex beads used for visualisation do fail to produce a strong signal. Besides Joinstar, Ritter and Hygisun, both saliva spit tests similar to Joinstar, also showed low sensitivity in our studies. While we could not find independent evaluation studies for these products, both can be found on the BfArM list (as of July 23, 2021; Supplemental Figure S3). Among the low ranked AgPOCTs, the sensitivity of Lepu medical was exceptionally low as this AgPOCT failed to deliver a visible positive test result in most replicates, even for the Ct16 sample. In addition to its poor performance in SARS-CoV-2 diagnostics, out of 20 performed Lepu medical tests three tests technically failed, indicated by the absence of the control band. Importantly, this last test is a very popular product in the area where this study was conducted, available at many drugstores and supermarket chains. Of note is also that Lepu medical differs from other AgPOCTs in its design and sample application. Technical failure did not occur in any of the other AgPOCTs, in which the immunochromatography paper is embedded in the common plastic cassettes. Taken together, comparison with published data for some of the investigated products confirmed our results. Therefore, we provide evidence that a rapid assessment of the sensitivity of SARS-CoV-2 AgPOCTs is feasible. It is important to mention that the volume of the lysis buffer provided with each AgPOCT varies between tests of different manufacturers resulting in a 2.6- to 20-fold dilution of the test samples during the procedure (Figure 1C). In this study, test results were not corrected for these different dilution factors, because the sample

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

dilution is an internal property of each test. Additionally, it is important to note that by using the same sample volume for each AgPOCT potential differences in swab properties, such as absorption volume, which affect the diagnostic sensitivity of AgPOCTs, are neglected. However, we note that for tests based on nasal swabs the used volume of 50 ul approximates the quantity absorbed by these swabs (Corman et al., 2021). Furthermore, there are AgPOCT-specific instructions for self-sampling. which can also influence the diagnostic sensitivity of a test. In light of these considerations we want to emphasize that this evaluation method only and exclusively focuses on comparing the technical sensitivity of the lateral flow test strips from different test manufacturers, in combination with the provided lysis buffers. Currently, there are more than 500 different products available for SARS-CoV-2 diagnostics, many of which lack independent assessment of their performance. In most cases the clinical sensitivity values provided by the manufacturer (e.g. in Figure 1C) are far >90%, however, detailed information on the used specimen collection and viral loads are usually not provided rendering these values largely inconclusive. Considering that individual products use different antibodies in varying amounts with different specificities and affinities sometimes recognizing different proteins in the viral particle with differing abundances, and diverse staining methods, these conspicuously similar values for clinical sensitivity given by the manufacturer are also unlikely. Therefore, an independent, rapid and critical evaluation of AgPOCTs available is required in order to determine the realistic performance of AgPOCT and especially to identify poor performing products. Given the huge number of products available for rapid SARS-CoV-2 diagnostics, in-depth studies evaluating the quality of AgPOCTs in a time-intensive procedure will not be available any time soon for all products available. Here we identify a non-functional product (Lepu medical) for

SARS-CoV-2 diagnostics, which was and still is (as of July 26, 2021) widely present in the region of Heidelberg, Germany, emphasizing the urgent need for AgPOCT products to undergo better and especially faster producer-independent quality control. The procedure presented here involving a reduced test sample collection and minimal labor represents a feasible strategy for prompt evaluation of available AgPOCTs for their usability in SARS-CoV-2 diagnostics. We provide a useful estimation of the limits of detection for the investigated AgPOCTs as the dimensions and trends are comparable to results from much more laborious in-depth studies. Therefore, we suggest this procedure as a rapid alternative to investigate Covid-19 AgPOCs in the absence of reliable data that validate the performance of a specific product.

perpetuity.
It is made available under a CC-BY-ND 4.0 International license .

Α	Means of T/C ratios						Pos. scores/ replicas C						Additional information					
	CIVE	, C127	ck2º	, CAS	, 4 ₆₀ .		Ct/8	ct21	_{ర్మనీ}	್ಯುಬ್ಬಿ	, 4eq		n	Sensitivity	Lysis buffer [µl]	Dil. factor		
Watmind	n.d.	1,81	0,51		0,00		n.d.	3/3	4/4	3/3	0/2	١.	2-4	90,45	300	6		
Clongene	n.d.	1,38	0,48	0,10	0,00		n.d.	3/3	4/4	4/4	0/3	١.	3-4	91,4	300	6		
MP	n.d.	1,08	0,28	0,04	0,00		n.d.	3/3	3/3	3/3	0/2	١.	2-3	96,19	250	5		
Boson	n.d.	1,05	0,22	0,02	0,00		n.d.	3/3	5/5	1/2	0/2	١.	2-5	96,19	200	4		
Biomerica	n.d.	0,78	0,22	0,06	0,00		n.d.	3/3	3/3	1/3	0/3	١.	3	94,7	300	6		
BTNX	n.d.	1,04	0,21	0,01	0,00		n.d.	3/3	3/3	0/3	0/3		3	90,6	300	6		
Medice	n.d.	0,92	0,20	0,03	0,00		n.d.	2/2	2/2	2/2	0/2		2	96,19	250	5		
Testsea	n.d.	0,79	0,16	0,01	0,00		n.d.	3/3	3/3	0/3	0/3		3	97,6	300	6		
Beier	n.d.	1,75	0,15	0,00	0,00		n.d.	2/2	2/2	0/2	0/2		2	96,5	450	9		
Laihe	n.d.	1,03	0,15	0,01	0,00		n.d.	3/3	4/4	1/3	0/2		2-4	95	300	6		
ACON	n.d.	0,94	0,15	0,02	0,00		n.d.	3/3	3/3	1/3	0/3		3	97,1	350	7		
Healgen	n.d.	0,93	0,13	0,01	0,00		n.d.	4/4	4/4	1/3	0/4		3-4	96,72	300	6		
möLab	n.d.	0,76	0,12	0,02	0,00		n.d.	2/2	3/3	2/3	0/2		2-3	97,25	300	6		
Teda	n.d.	0,87	0,12	0,00	0,00		n.d.	4/4	4/4	0/3	0/4		3-4	93,87	350	7		
Wondfo	n.d.	0,98	0,11	0,00	0,00		n.d.	2 /2	2/3	0/2	0/2		2-3	97,83	400	8		
Abbott	n.d.	1,20	0,09	0,00	0,00		n.d.	4/4	3/4	0/3	0/4		3-4	98,1	300	6		
nal von minden	0,48	0,50	0,09	0,01	0,00		2/2	4/4	4/4	0/3	0/4		2-4	94,1	350	7		
Realy	n.d.	0,89	0,09	0,01	0,00		n.d.	2/2	3/3	0/3	0/2		2-3	92,9	130	2,6		
NanoRepro	0,77	0,56	0,08	0,00	0,00		2/2	3/3	3/3	0/3	0/2		2-4	97,33	500	10		
SD Biosensor	n.d.	1,12	0,07	0,00	0,00		n.d.	4/4	3/4	0/3	0/4		3-4	83,3	300	6		
Deepblue	n.d.	0,67	0,07	0,00	0,00		n.d.	2/2	3/3	0/3	0/2		2-3	96,4	300	6		
OFM	n.d.	0,92	0,07	0,00	0,00		n.d.	3/3	3/3	0/3	0/2		2-3	96,8	400	8		
Hotgen	n.d.	0,68	0,06	0,00	0,00		n.d.	3/3	3/4	0/3	0/3		3-4	95,37	300	6		
fameditec	n.d.	0,51	0,06	0,00	0,00		n.d.	3/3	3/3	0/2	0/2		2-3	96,3	250	5		
Sanicom	1,10	0,63	0,06	0,00	0,00		2/2	3/3	3/3	0/3	0/2		2-4	96,1	1000	20		
RapiGEN	n.d.	0,99	0,05	0,00	0,00		n.d.	3/3	2/3	0/3	0/3		3	96	350	7		
Safecare	0,52	0,43	0,05	0,00	0,00		3/3	3/3	3/3	0/3	0/3		3	97,04	350	7		
Joysbio	0,30	0,31	0,03	0,00	0,00		2/2	3/3	2/3	0/3	0/3		2-3	98,13	350	7		
Ritter	n.d.	0,16	0,02	0,00	0,00		n.d.	2/2	0/3	0/3	0/2		2-3	95,1	500	10		
Joinstar	0,10	0,09	0,02	0,00	0,01		2/2	3/3	1/3	0/3	0/3		2-3	92,2	1000	20		
Hygisun	n.d.	0,36	0,01	0,00	0,00		n.d.	3/3	1/3	0/3	0/3		3	98,94	1000	20		
Lepu Medical	0,07	0,00	0,00	n.d.	0,00		3/7	1/8	0/1	n.d.	0/2		1-8	95,06	150	3		

Figure 1: Quantitative and qualitative evaluation of 32 SARS-CoV-2 AgPOCTs in a rapid sensitivity assessment approach. (A) Investigated AgPOCT are listed with the means of T/C ratios (test band (T) intensity to control (C) band intensity) for each Ct test sample. T/C ratios are color-coded in shades of red (highest values with most intensive red). Blue color highlights zeros indicating the absence of measurable signal at the test band position. Ct16 test sample was only used on AgPOCTs with exceptionally low performance in detection of the Ct21 sample. AgPOCTs are ranked according to their T/C_{Ct25} ratio. (B) Scoring results of visual inspection for all replicates. Full reproducibility of positive scores in all replicates is highlighted in green, positive scores in the majority of replicates in yellow, positive scores in the minority of replicates in orange and no positive scores in any replicate is light red. n.d. = not determined (grey). Double line indicates the limit of reliable detection of SARS-CoV-2 positive samples (reliability defined by reproducibility of positive scores in all or

most replicates of a given Ct test sample). (C) Additional information on investigated AgPOCTs: Sensitivities of AgPOCTs according to the corresponding manufacturer's package insert, volumes of provided lysis buffer and the resulting dilution factor for the Ct test samples $(V = 50 \mu I)$ are given.




Figure 2: Representative images of SARS-CoV-2 AgPOCTs lateral flow test stripes treated with corresponding Ct test samples. Contrast settings were optimized for each AgPOCT example image set in order to ensure best visibility of the test bands. AgPOCT example images are arranged (from left top to right bottom) according to the ranking presented in Figure 1. Red line indicates the limit of reliable detection (see Figure 1A, B).

perpetuity.

It is made available under a CC-BY-ND 4.0 International license .

386 References

- 387 **Bekliz**, M., Adea, K., Essaidi-Laziosi, M., Sacks, J. A., Escadafal, C., Kaiser, L., &
- 388 Eckerle, I. (2021). Analytical comparison of nine SARS-CoV-2 antigen-detecting
- rapid diagnostic tests for emerging SARS-CoV-2 variants. MedRxiv, 114(June),
- 390 e00146. Retrieved from https://doi.org/10.1016/j.sciaf.2019.e00146
- 391 Berger, A., Nsoga, M. T. N., Perez-Rodriguez, F. J., Aad, Y. A., Sattonnet-Roche, P.,
- 392 Gayet-Ageron, A., ... Eckerle, I. (2021). Diagnostic accuracy of two commercial
- 393 SARSCoV- 2 antigen-detecting rapid tests at the point of care in community-based
- 394 testing centers. PLoS ONE, 16(3 March 2021), 1–12.
- 395 https://doi.org/10.1371/journal.pone.0248921
- 396 Brümmer, L. E., Katzenschlager, S., Gaeddert, M., Erdmann, C., Schmitz, S., Bota,
- 397 M., ... Denkinger, C. M. (2021). The accuracy of novel antigen rapid diagnostics for
- 398 SARS-CoV-2: a living systematic review and meta-analysis. MedRxiv,
- 399 2021.02.26.21252546. Retrieved from https://doi.org/10.1101/2021.02.26.21252546
- 400 Corman, V. M., Haage, V. C., Bleicker, T., Schmidt, M. L., Mühlemann, B.,
- 401 Zuchowski, M., ... Drosten, C. (2021). Comparison of seven commercial SARS-CoV-
- 402 2 rapid point-of-care antigen tests: a single-centre laboratory evaluation study. The
- 403 Lancet Microbe, 5247(21), 1–9. https://doi.org/10.1016/S2666-5247(21)00056-2
- 404 Cubas-Atienzar, A. I., Kontogianni, K., Edwards, T., Buist, K., Thompson, C. R.,
- 405 Williams, C. T., ... Adams, R. (2021). Limit of detection in different matrices of
- 406 nineteen commercially available rapid antigen tests for the detection of SARS-CoV-2
- 407 Liverpool School of Tropical Medicine, Centre for Drugs and Diagnostics, Liverpool,
- 408 L3 5QA , UK Liverpool School of Tropical. Retrieved from
- 409 https://www.medrxiv.org/content/10.1101/2021.03.19.21253950v1.full.pdf
- 410 **Dinnes**, J., Deeks, J. J., Adriano, A., Berhane, S., Davenport, C., Dittrich, S., ... Van
- 411 den Bruel, A. (2020). Rapid, point-of-care antigen and molecular-based tests for
- 412 diagnosis of SARS-CoV-2 infection. Cochrane Database of Systematic Reviews,
- 413 2020(8). https://doi.org/10.1002/14651858.CD013705
- 414 Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel
- 415 und Medizinprodukte (BfArM)). Antigen-Tests zum direkten Erregernachweis des
- 416 Coronavirus.
- 417 https://antigentest.bfarm.de/ords/f?p=110:100:16622641307467:::::&tz=2:00
- 418 **Iglòi**, Z., Velzing, J., Van Beek, J., Van de Vijver, D., Aron, G., Ensing, R., ...
- 419 Molenkamp, R. (2021). Clinical evaluation of roche sd biosensor rapid antigen test for
- 420 sars-cov-2 in municipal health service testing site, the netherlands. Emerging
- 421 Infectious Diseases, 27(5), 1323–1329. https://doi.org/10.3201/eid2705.204688
- Jegerlehner, S., Suter-riniker, F., Jent, P., Bittel, P., & Nagler, M. (2021). Diagnostic
- 423 accuracy of a SARS-CoV-2 rapid antigen test in real-life clinical settings. International
- 424 Journal of Infectious Diseases, 109, 118–122.
- 425 https://doi.org/10.1016/j.ijid.2021.07.010

perpetuity.
It is made available under a CC-BY-ND 4.0 International license .

- 426 **Kohmer**, N., Toptan, T., Pallas, C., Karaca, O., Pfeiffer, A., Westhaus, S., ...
- 427 Rabenau, H. F. (2021). The Comparative Clinical Performance of Four SARS-CoV-2
- 428 Rapid Antigen Tests and Their Correlation to Infectivity In Vitro. Journal of Clinical
- 429 Medicine, 10(2), 328. https://doi.org/10.3390/jcm10020328
- 430 Krüger, L. J., Klein, J. A. F., Tobian, F., Gaeddert, M., Lainati, F., Klemm, S., ...
- Jones, T. C. (2021). Evaluation of accuracy, exclusivity, limit-of-detection and ease-
- 432 of-use of LumiraDxTM Antigen-detecting point-of-care device for SARS-CoV-2.
- 433 MedRxiv, 1-37.
- 434 Merino, P., Guinea, J., Munoz-Gallego, I., González-Donapetry, P., Galán, J. C.,
- 435 Antona, N., ... Group, the S. P. T. C.-19 validation. (2021). Multicenter evaluation of
- 436 the PanbioTM COVID-19 rapid antigen- detection test for the diagnosis of SARS-
- 437 CoV-2 infection. Clinical Microbiology and Infection, 27(January), 758–761.
- Nordgren, J., Sharma, S., Olsson, H., Jämtberg, M., Falkeborn, T., Svensson, L., &
- 439 Hagbom, M. (2021). SARS-CoV-2 rapid antigen test: High sensitivity to detect
- infectious virus. Journal of Clinical Virology, 140(January).
- Paul Ehrlich Institute (PEI), Federal Institute for Vaccines and Biomedicines (12
- 442 July, 2021). Vergleichende Evaluierung der Sensitivität von SARS-CoV-2
- 443 Antigenschnelltests.
- 444 https://www.pei.de/SharedDocs/Downloads/DE/newsroom/dossiers/evaluierung-
- sensitivitaet-sars-cov-2-antigentests-04-12-2020.pdf?__blob=publicationFile&v=48
- 446 **Puyskens**, A., Krause, E., Michel, J., Nübling, M., Scheiblauer, H., Bourguain, D., ...
- 447 Nitsche, A. (2021). Establishment of an evaluation panel for the decentralized
- 448 technical evaluation of the sensitivity of 31 rapid detection tests for SARS-CoV-2
- 449 diagnostics. MedRxiv.
- 450 **Scheiblauer**, H., Filomena, A., Nitsche, A., Puyskens, A., Corman, V. M., Drosten,
- 451 C., ... Nübling, C. M. (2021). Comparative sensitivity evaluation for 122 CE-marked
- 452 SARS-CoV-2 antigen rapid tests. MedRxiv, 2021.05.11.21257016. Retrieved from
- 453 http://medrxiv.org/content/early/2021/05/12/2021.05.11.21257016.abstract
- 454 **Schildgen**, V., Demuth, S., Lüsebrink, J., & Schildgen, O. (2021). Limits and
- 455 opportunities of sars-cov-2 antigen rapid tests: An experienced-based perspective.
- 456 Pathogens, 10(1), 1–7. https://doi.org/10.3390/pathogens10010038
- 457 **Seynaeve**, Y., Heylen, J., Fontaine, C., Maclot, F., Meex, C., Diep, A. N., ... Descy,
- 458 J. (2021). Evaluation of Two Rapid Antigenic Tests for the Detection of SARS-CoV-2
- in Nasopharyngeal Swabs. Journal of Clinical Medicine, (M), 1–9.
- 460 **Stokes**, W., Berenger, B. M., Portnoy, D., Scott, B., Szelewicki, J., Singh, T., ...
- Tipples, G. (2021). Clinical performance of the Abbott Panbio with nasopharyngeal,
- 462 throat, and saliva swabs among symptomatic individuals with COVID-19. European
- 463 Journal of Clinical Microbiology and Infectious Diseases, 3-8.
- 464 https://doi.org/10.1007/s10096-021-04202-9
- 465 **Strömer**, A., Rose, R., Schäfer, M., Schön, F., Vollersen, A., Lorentz, T., ...
- 466 Krumbholz, A. (2021). Performance of a point-of-care test for the rapid detection of

- 467 sars-cov-2 antigen. Microorganisms, 9(1), 1–11.
- https://doi.org/10.3390/microorganisms9010058 468
- Wagenhäuser, I., Knies, K., Rauschenberger, V., Eisenmann, M., McDonogh, M., 469
- Petri, N., ... Krone, M. (2021). Clinical performance evaluation of SARS-CoV-2 rapid 470
- 471 antigen testing in point of care usage in comparison to RT-qPCR. EBioMedicine, 69,
- 103455. https://doi.org/10.1016/j.ebiom.2021.103455 472
- 473 World Health Organization (WHO; 11 September 2020). Antigen-detection in the
- 474 diagnosis of SARS-CoV-2 infection using rapid immunoassays: Interim guidance.
- 475 WHO/2019-nCoV/Antigen_Detection/2020.

Acknowledgements

476

- We thank Helena Kettern, Vincent T. Jaschinski and Larissa Karl for their flexible
- 478 help with AgPOCT image acquisition. Furthermore, we thank M. Krogemann for help
- with AgPOCT result scoring. Additionally, we thank M. Meurer for helpful discussions.